Home » Stocks » ICON plc

ICON plc (ICLR)

Stock Price: $189.94 USD 2.04 (1.09%)
Updated Aug 12, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 10.00B
Revenue (ttm) 2.77B
Net Income (ttm) 373.99M
Shares Out 52.63M
EPS (ttm) 6.00
PE Ratio 31.66
Forward PE 30.03
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 12, 2020
Last Price $189.94
Previous Close $187.90
Change ($) 2.04
Change (%) 1.09%
Day's Open 189.71
Day's Range 188.06 - 191.29
Day's Volume 146,779
52-Week Range 104.28 - 199.83

More Stats

Market Cap 10.00B
Enterprise Value 9.85B
Earnings Date (est) Oct 21, 2020
Ex-Dividend Date n/a
Shares Outstanding 52.63M
Float 51.97M
EPS (basic) 6.85
EPS (diluted) 6.00
FCF / Share 6.72
Dividend n/a
Dividend Yield n/a
Earnings Yield 3.16%
FCF Yield 3.62%
Payout Ratio n/a
Shares Short 592,066
Short Ratio 2.26
Short % of Float 0.98%
Beta 0.86
PE Ratio 31.66
Forward PE 30.03
P/FCF Ratio 27.62
PS Ratio 3.61
PB Ratio 6.26
Revenue 2.77B
Operating Income 433.41M
Net Income 373.99M
Free Cash Flow 361.90M
Net Cash 143.70M
Net Cash / Share 2.73
Gross Margin 31.11%
Operating Margin 15.64%
Profit Margin 13.30%
FCF Margin 13.06%
ROA 9.11%
ROE 21.59%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (18)

Buy 8
Overweight 0
Hold 9
Underweight 0
Sell 1

Analyst Consensus: Overweight

Price Target

$199.20*
(4.88% upside)
Low
170
Current: $189.94
High
220
Target: 199.20
*Average 12-month price target from 15 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue2,8062,5961,7581,6661,5751,5031,3361,115946900
Revenue Growth8.09%47.62%5.52%5.81%4.77%12.52%19.83%17.9%5.08%-
Gross Profit832778731705666600491397334359
Operating Income43337333831228220212168.0229.4492.10
Net Income37432328126224017210355.4222.8887.07
Shares Outstanding53.8654.1254.1355.2558.7561.5060.9159.9760.3859.72
Earnings Per Share6.795.895.134.653.972.731.650.920.371.44
EPS Growth15.28%14.81%10.32%17.13%45.42%65.45%79.35%148.65%-74.31%-
Operating Cash Flow41326938325927916922111320.1987.43
Capital Expenditures-50.65-48.40-44.72-42.60-49.73-32.78-29.49-30.79-35.28-30.95
Free Cash Flow36222033821722913619282.64-15.0956.48
Cash & Equivalents570456360261190216321190174256
Total Debt426349349349348-----
Net Cash / Debt14410611.56-87.92-158216321190174256
Assets2,9082,3542,1471,8261,7171,5291,4421,2021,028950
Liabilities1,2501,000956881954579532448346280
Book Value1,6181,3541,191945763950911755682670
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name ICON plc
Country Ireland
Employees 15,150
CEO Stephen A. Cutler

Stock Information

Ticker Symbol ICLR
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: ICLR
IPO Date May 15, 1998

Description

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. The company's clinical development services include product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. Its clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. The company was founded in 1990 and is headquartered in Dublin, Ireland.